CIK 0001590877
- Non-accelerated filer
- Smaller reporting company
REGENXBIO Inc.
Sign in to watch- Ticker
- RGNX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 471851754
- Phone
- +1 240-552-8181
- Business address
- 9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
- Former names
- ReGenX Biosciences, LLC
- 4 Open-market sale President and CEO sold 6,500 shares at $20.05 ($130,325)
- 4 Open-market sale Chief Financial Officer sold 3,040 shares at an average $21.09 ($64,111)
- 4 Open-market sale Chief Medical Officer sold 15,000 shares at $18.66 ($279,900)
- 4 Open-market sale President and CEO sold 6,500 shares at $18.66 ($121,290)
- 4 Open-market sale Chief Financial Officer sold 3,100 shares at $19.81 ($61,411)
- 4 Open-market sale Chief Medical Officer sold 15,000 shares at an average $19.68 ($295,157)
- 4 Open-market sale President and CEO sold 6,500 shares at an average $19.68 ($127,902)
- 4 Open-market sale Chief Financial Officer sold 3,100 shares at $18.75 ($58,125)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market sale Director sold 8,599 shares at $19.04 ($163,725)
- 4 Open-market sale Chief Financial Officer sold 3,100 shares at $19.07 ($59,117)
- 4 Open-market sale Director sold 10,000 shares at $18.35 ($183,500)
- 4 Open-market sale Director sold 30,000 shares at an average $22.26 ($667,736)
- 4 Open-market sale President and CEO sold 15,440 shares at an average $20.98 ($323,955)
Page 18 of 22 · 435 filings